The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R
1
and NR
2
R
3
and a maximum chain length of 4 atoms extending between E and NR
2
R
3
, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR
2
R
3
group and provided that the oxo group when present is located at a carbon atom a with respect to the NR
2
R
3
group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R is an aryl or heteroaryl group; and R
2
, R
3
, R
4
and R
5
are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents.
该发明提供了一种组合物,包括一个辅助化合物(例如一个、两个或更多个辅助化合物)和具有蛋白激酶B抑制活性的式(I)化合物:其中A是含有1至7个
碳原子的饱和
碳氢链连接基团,连接基团在R1和NR2R3之间延伸的最大链长为5个原子,在E和NR2R3之间延伸的最大链长为4个原子,其中连接基团中的一个
碳原子可以选择性地被
氧原子或
氮原子取代;连接基团A的
碳原子可以选择性地携带来自
酮基、
氟和羟基的一个或多个取代基,前提是当羟基存在时,不位于相对于NR2R3基团的
碳原子a处,且当
酮基存在时,位于相对于NR2R3基团的
碳原子a处;E是单环或双环
碳环或杂环基团;R是芳基或杂芳基团;R2、R3、R4和R5如权利要求中所定义。还提供了患者包装、药物配套和包装以及含有这些组合物的组合物、制备这些组合物的方法以及它们作为抗癌剂的联合治疗中的用途。